Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New sequencers are poised to disrupt Illumina’s dominance. Users will need to navigate the opportunities and challenges on offer in an increasingly crowded market.
Recent trial failures have called into question the central role of α-synuclein in Parkinson’s disease pathology. Although many continue to target α-synuclein aggregates in the brain, others are paying attention to the endolysosomal pathway, mitochondria and even glucose metabolism.
Immunomodulatory drug treats psoriasis by a new mechanism: the selective deactivation of TYK2 through its catalytically defective domain, the pseudokinase.
Industry celebrates two newly approved genetic medicines, but patients with these blood disorders may face a long wait, and many will never access them because of their high cost.
Researchers are designing diets that may improve patient responses to cancer therapy by using machine learning and genotyping to uncover tumors’ nutritional vulnerabilities.
Biodefense stockpiles are helping to curb the monkeypox outbreak, but the vaccines are based on old technology with significant side effects. Are other vaccines on the horizon?
Drug hunters are moving into the clinic with human-first ‘no-hypothesis’ target discovery, applying the full force of machine learning to massive collections of human omics data.
Companies are deploying siRNA and antisense oligonucleotides to tackle dangerously high cholesterol driven by genetics, betting that a wider population will benefit.